Keros Therapeutics (NASDAQ:KROS) Raised to "Sell" at Wall Street Zen

Key Points

• Wall Street Zen upgraded Keros Therapeutics from “strong sell” to “sell,” while analysts remain divided: four rate the stock a Buy, three a Hold and two a Sell. The consensus rating is “Hold,” with an average price target of $20.50.
• KROS opened at $11.15, near the lower end of its 52-week range of $9.69 to $22.55, and has a market capitalization of approximately $221 million. The company reported quarterly EPS of -$1.45, missing estimates of -$1.34, and analysts expect a full-year loss of $5.12 per share.
• Insiders sold 8,425 shares worth about $90,000 over the past 90 days, while institutional investors and hedge funds own 71.56% of the stock. Keros is developing therapies for anemia and related blood disorders, including its lead candidate KER-050.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) was upgraded by research analysts at Wall Street Zen from a "strong sell" rating to a "sell" rating in a report released on Saturday.

KROS has been the subject of several other research reports. Zacks Research cut shares of Keros Therapeutics from a "hold" rating to a "strong sell" rating in a report on Wednesday, July 29th. Leerink Partners dropped their price objective on shares of Keros Therapeutics from $30.00 to $23.00 and set an "outperform" rating on the stock in a report on Tuesday. HC Wainwright reaffirmed a "buy" rating and issued a $20.00 price objective on shares of Keros Therapeutics in a research report on Tuesday. Weiss Ratings cut shares of Keros Therapeutics from a "sell (d)" rating to a "sell (d-)" rating in a research report on Friday, May 15th. Finally, Wells Fargo & Company reduced their target price on shares of Keros Therapeutics from $20.00 to $18.00 and set an "overweight" rating for the company in a research note on Tuesday. Four research analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and an average target price of $20.50.

Keros Therapeutics Price Performance

NASDAQ:KROS opened at $11.15 on Friday. Keros Therapeutics has a fifty-two week low of $9.69 and a fifty-two week high of $22.55. The stock has a market capitalization of $221.10 million, a PE ratio of -3.01 and a beta of 0.99. The business's 50-day simple moving average is $10.62 and its 200-day simple moving average is $12.39.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last issued its quarterly earnings data on Monday, August 3rd. The company reported ($1.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.34) by ($0.11). Keros Therapeutics had a negative net margin of 256.60% and a negative return on equity of 21.40%. On average, research analysts expect that Keros Therapeutics will post -5.12 earnings per share for the current year.

Insider Transactions at Keros Therapeutics

In other news, Director Julius Knowles sold 2,625 shares of the firm's stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $10.73, for a total transaction of $28,166.25. Following the completion of the transaction, the director directly owned 10,958 shares of the company's stock, valued at $117,579.34. This trade represents a 19.33% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Alpna Seth sold 2,625 shares of Keros Therapeutics stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $10.72, for a total transaction of $28,140.00. Following the completion of the sale, the director owned 9,767 shares in the company, valued at $104,702.24. This trade represents a 21.18% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 8,425 shares of company stock valued at $89,994 in the last ninety days. 12.60% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Keros Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. AQR Capital Management LLC acquired a new position in shares of Keros Therapeutics during the 1st quarter worth about $226,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Keros Therapeutics by 15.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,166 shares of the company's stock valued at $227,000 after acquiring an additional 2,982 shares during the last quarter. Goldman Sachs Group Inc. increased its position in shares of Keros Therapeutics by 38.3% in the first quarter. Goldman Sachs Group Inc. now owns 740,606 shares of the company's stock valued at $7,547,000 after acquiring an additional 205,022 shares during the last quarter. Creative Planning raised its holdings in Keros Therapeutics by 40.2% during the second quarter. Creative Planning now owns 24,226 shares of the company's stock worth $323,000 after acquiring an additional 6,948 shares in the last quarter. Finally, Rhumbline Advisers raised its holdings in Keros Therapeutics by 16.0% during the second quarter. Rhumbline Advisers now owns 51,815 shares of the company's stock worth $692,000 after acquiring an additional 7,146 shares in the last quarter. 71.56% of the stock is currently owned by institutional investors and hedge funds.

About Keros Therapeutics

Keros Therapeutics, Inc NASDAQ: KROS is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company's research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company's lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source